# OnCo record nct05116462 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05116462/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05116462", "NCT05116462" ;
  schema:name "Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer"@en ;
  schema:alternateName "ORIENT-99"@en ;
  schema:description "A phase 3 trial of Pemetrexed, Carboplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05116462/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05116462> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-03-15" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/sintilimab/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/innovent/> .